Functional characterization of human peptide/histidine transporter 1 in stably transfected MDCK cells.

Feifeng Song,Yongjun Hu,Yuqing Wang,David E Smith,Huidi Jiang

DOI: https://doi.org/10.1021/acs.molpharmaceut.7b00728

2018-01-01

Molecular Pharmaceutics

Abstract:The proton-coupled oligopeptide transporter PHTI (SLC15A4), which facilitates cross-membrane transport of histidine and small peptides from inside the endosomes or lysosoines to cytosol, plays an important role in intracellular peptides homeostasis and innate immune responses. However, it remains a challenge to elucidate functional properties of the PHTI transporter because of its subcellular localization. The purpose of this study was to resort hPHT1 protein from the subcellular to outer cell membrane of MDCK cells stably transfected with human PHT1 mutants, and to characterize its functional activity in these cells. Using this model, the functional activity of hPHT1 was evaluated by cellular uptake studies with d(3)-L-histidine, GlySar, and the bacterial peptidoglycan products MDP and Tri-DAP. We found that the disruption of two dileucine motifs was indispensable for hPHT1 transporter being preferentially targeting to plasma membranes. hPHT1 showed high affinity for d(3)-L-histidine and low affinity for GlySar, with K-m values of 16.3 +/- 1.9 mu M and 1.60 +/- 0.30 mM, respectively. Moreover, the bacterial 'peptidoglycan components MDP and Tri-DAP were shown conclusively to be hPHT1 substrates. The uptake of MDP by hPHT1 was inhibited by di/tripeptides and peptide-like drugs, but not by glycine and acyclovir. The functional activity of hPHT1 was also pH-dependent, with an optimal cellular uptake in buffer pH 6.5. Taken together, we established a novel cell model to evaluate the function of hPHT1 in vitro, and confirmed that MDP and Tri-DAP were substrates of hPHT1. Our findings suggest that PHT1 may serve as a potential target for reducing the immune responses and for drug treatment of inflammatory diseases.